Qritive

Both the models and the platform are Qritive's. The QAi modules are deep learning models for prostate detection and grading, colon biopsies, lymph node metastases and IHC scoring of Ki-67, HER2 and PD-L1, and they are sold on their own into other image management systems, including through Sectra's Amplifier Marketplace, as well as inside Qritive's Pantheon. Pantheon itself handles case management, slide viewing, reporting and telepathology and holds its own device registration, so a laboratory could run it with no model.

The model is the engine of core modules while the platform carries value without it.

An assistive design with visible reasoning, and no stated threshold. The modules are described as supporting pathologists, with QAi Prostate producing segmentation maps of benign and malignant regions and a summary report, and the lymph node module directing attention to areas of concern. The prostate modules are also offered for screening, triage and prioritization of cases, which changes the order in which a pathologist sees work. The Abu Dhabi approval is for clinical decision support, and its assessment stressed clinical oversight. Nothing states the confidence at which a case is prioritized or deprioritized, or what happens when triage places a malignant case low in the queue.

The oversight structure described, with the threshold missing.

The modules are described by task and as deep learning, with nothing identified. The company says QAi Colon Dx, QAi Lymph Node Dx and QAi HER2 Quant use deep learning and that QAi Prostate Grade uses AI-based tumor classification with segmentation maps, and that its modules are developed under IEC 62304. No architecture, training data, version or update practice is published for any module, and the journals the company says feature its validation are not cited.

Architecture described in general terms with nothing identified.

An in-house build, with outside processors described only by type. Qritive develops its own modules, so no outside model provider sits between a slide and a result. Its privacy notice says Qritive acts as processor for pseudonymized DICOM images and case data under a data processing agreement, and shares data with contracted companies providing storage, analytics and IT support, without naming them; Amazon Web Services, Dell, NTT, NVIDIA and Philips appear as partners on the home page without their roles stated. When modules run inside another company's platform, where they execute is not stated.

A structurally short chain at the model layer, with the operating chain unnamed.

Named customers and regulatory reviews, with no published performance. Named adopters include Metropolis Healthcare, the Rajiv Gandhi Cancer Institute and Research Centre, whose use of QAi Prostate Grade the company presents in a video case study, and Dr. Lal PathLabs, which selected the lymph node module in 2025. QAi Prostate Grade passed a premarket evaluation for Singapore's Class C registration and a health technology assessment in Abu Dhabi, but neither review's findings are published. The company says its modules are clinically validated and featured in leading journals without citing a study, and no sensitivity, specificity or concordance figure is published for any module.

Named customers with no published outcome figures.

General assurances that reach the product, without answering what reaches a model. The privacy notice covers Pantheon as well as the website: Qritive processes pseudonymized DICOM images with embedded metadata and anonymized case information as processor for its customers under a data processing agreement, and says it does not commercially exploit personal data. It also lists improving and developing the services among its purposes, without saying whether customer images may train models, and states no retention period for images. No safety engineering is published.

General assurances that do not answer what reaches a model.

A processor position is stated in a privacy notice that reaches the product. The notice covers the website and the Pantheon application, says Qritive acts as data processor for customers' pseudonymized images and case data, with the customer as controller, under a data processing agreement effective from first use, and is construed under GDPR, Singapore and Indian law and HIPAA; the security page shows a HIPAA compliance mark. The data processing agreement itself is not published, and no business associate agreement is mentioned for US customers.

A processor status documented in a substantive privacy notice, with the agreement unpublished.

A recognized certification named with its number and scope, plus a linked trust center. Qritive's security page states ISO/IEC 27001:2022 certification (certificate IC-IS-2407061) covering its AI pathology software and its data handling, alongside ISO 13485:2016 (SG19/81841808), and says its controls are monitored with automated tools and verified by external auditors. It links a trust center at trust.qritive.com, which may offer the reports for download.

Authorizations for the prostate module in Singapore and Abu Dhabi, with no US position stated. QAi Prostate Grade received Class C in vitro diagnostic registration from Singapore's Health Sciences Authority after a premarket evaluation, and market approval from Abu Dhabi's Department of Health after a health technology assessment, for clinical decision support. Pantheon is a Class A device in Singapore and CE marked. The other modules carry no stated clinical authorization, and nothing states the modules' status in the United States, where the company has operations. FDA's databases list no Qritive device.

Non-US regimes named, with the marketing matching them.

A responsible AI commitment with no evaluation behind it. The company's security and compliance page is headed ensuring safe, trusted and responsible AI in pathology, and says its modules are developed under IEC 62304 and ISO 13485. No results are published by laboratory, scanner, stain or patient group for any module, although the modules are used across Singapore, India and the United Arab Emirates, where tissue preparation and populations differ, and Gleason grade agreement is least reliable at the grade group boundaries where treatment changes.

Policy commitment with no evaluation behind it.

Outputs a pathologist can inspect, and nothing standing behind them. QAi Prostate shows segmentation maps of the regions it classified and a report of the tissue areas behind its result, so a pathologist can see where a call came from and reject it, and the Abu Dhabi approval is for decision support with clinical oversight. No error rate is published, and no warranty, indemnity or remediation commitment attaches to a wrong grade. When a module runs inside another company's platform, nothing states whether Qritive or the host answers for its errors.

Mechanisms to challenge an output, with nothing standing behind it.

Named image platforms carry the modules; laboratory and record integration is claimed without names. The home page lists Roche and Corista among compatible pathology systems and says the modules are featured on Sectra's Amplifier Marketplace, and Pantheon accepts all widely used slide formats and supports external AI modules. Pantheon is said to integrate with major laboratory, record and hospital information systems, but none is named, and no interface or standard is described.

Named systems carrying output in one direction.

On premises or cloud deployment, with the cloud route's location unstated. Pantheon is offered for on premises and cloud deployment, and the modules also run inside other companies' platforms. On premises keeps images at the laboratory. For the cloud route no host, region or tenant isolation is stated, and the privacy notice says data may be processed by third parties inside and outside the European Union.

Options stated with residency committed only for the on premises route.

No price is published, and the sales routes can be established. Pantheon is sold as an image management platform for on premises or cloud use, the QAi modules are sold with it or on their own inside other platforms, including through Sectra's Amplifier Marketplace, and Qritive Academy offers pathology education. No platform, module or per case price is published, and nothing says how module pricing differs between Pantheon and a host platform.

The sales posture is discoverable, with no price.

Broad coverage named, with regulatory review behind prostate grading. The modules cover prostate detection and grading, colon biopsies, lymph node metastases and IHC scoring of Ki-67, HER2 and PD-L1, for clinical and research settings, with named users in Singapore, India and Abu Dhabi. QAi Prostate Grade has passed regulatory review in Singapore and Abu Dhabi; the other modules have no published validation or authorization.

Coverage named with validation behind part of it.